Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

Company Overview

Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise dedicated to discovering and developing medicines that improve patients’ lives. With a research-driven approach, the company focuses on four core therapeutic areas: oncology, gastroenterology, neuroscience, and rare diseases. It engages in both small molecule and biologics research, leveraging cutting-edge technologies such as gene therapy and cell therapy to bring innovative treatments from lab to market.

Among Takeda’s notable products are therapies for inflammatory bowel disease, multiple myeloma, and hereditary angioedema, as well as newer treatments targeting rare genetic disorders. The company maintains a robust pipeline spanning preclinical studies through late-stage clinical trials. Strategic collaborations with academic institutions, biotechnology firms, and research consortia further bolster its development efforts and foster the exchange of scientific expertise.

Founded in 1781 in Doshomachi, Osaka, by Chobei Takeda I, the company has grown from a local traditional medicine producer into one of the world’s largest pharmaceutical firms. A major milestone occurred in 2019 when Takeda acquired Shire plc, significantly expanding its rare disease and neuroscience portfolios and enhancing its global footprint. Today, Takeda operates in more than 80 countries and regions across the Americas, Europe, Asia Pacific, Africa, and the Middle East, with research centers in Japan, the United States, Europe, and Canada.

Under the leadership of CEO Christophe Weber, Takeda emphasizes patient-centric innovation, sustainability, and ethical business practices. The management team prioritizes long-term growth through disciplined investment in R&D, as well as environmental and social responsibility initiatives. Takeda’s governance framework is designed to maintain high standards of transparency and accountability while advancing its mission to deliver better health and a brighter future for people worldwide.

Key Stats

• Today's Range: $14.41 to $14.72
• 50-Day Range: $13.69 to $15.55
• 52-Week Range: $12.80 to $15.53
• Volume: 3.64 million shs
• Average Volume: 2.03 million shs
• Market Capitalization: $45.88 billion
• P/E Ratio: 65.55
• Dividend Yield: 3.81%
• Price Target: N/A
• Consensus Rating: Buy

Takeda Pharmaceutical Stock Analysis - MarketRank™

Takeda Pharmaceutical scored higher than 40% of companies evaluated by MarketBeat, and ranked 704th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Takeda Pharmaceutical.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 0.61%

Earnings Growth

Earnings for Takeda Pharmaceutical are expected to grow by 0.61% in the coming year, from $1.64 to $1.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Takeda Pharmaceutical is 65.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of Takeda Pharmaceutical is 65.55, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.01.

Price to Book Value per Share Ratio

Takeda Pharmaceutical has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Takeda Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Takeda Pharmaceutical has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Takeda Pharmaceutical has recently decreased by 21.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 3.74%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Takeda Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Takeda Pharmaceutical is 250.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 33.33% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.16% of the float of Takeda Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Takeda Pharmaceutical has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Takeda Pharmaceutical has recently decreased by 21.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.10

News Sentiment

Takeda Pharmaceutical has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Takeda Pharmaceutical this week, compared to 5 articles on an average week.

MarketBeat Follows

2 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.

Percentage Held by Institutions

Only 9.17% of the stock of Takeda Pharmaceutical is held by institutions.

TAK Stock Analysis - Frequently Asked Questions

How have TAK shares performed this year?

Takeda Pharmaceutical's stock was trading at $13.24 on January 1st, 2025. Since then, TAK stock has increased by 8.9% and is now trading at $14.42.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co. (NYSE:TAK) posted its earnings results on Thursday, May, 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by $0.08. The company earned $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a trailing twelve-month return on equity of 10.64% and a net margin of 2.36%.
Read the conference call transcript.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiaries of Takeda Pharmaceutical: PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and others.

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's top institutional investors include Clean Yield Group (0.01%), Gold Investment Management Ltd., Signaturefd LLC and Wealth Enhancement Advisory Services LLC.
View institutional ownership trends.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:TAK
• CIK: 1395064
• Web: www.takeda.com
• Phone: (166) 204-2111
• Fax: 813-3278-2268
• Employees: 47,455
• Year Founded: 1781

Profitability

• EPS (Trailing Twelve Months): $0.22
• Trailing P/E Ratio: 65.93
• Forward P/E Ratio: 8.84
• P/E Growth: N/A
• Net Income: $712.33 million
• Net Margins: 2.36%
• Pretax Margin: 3.82%
• Return on Equity: 10.64%
• Return on Assets: 5.14%

Debt

• Debt-to-Equity Ratio: 0.57
• Current Ratio: 1.01
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: $30.09 billion
• Price / Sales: 1.53
• Cash Flow: $3.13 per share
• Price / Cash Flow: 4.63
• Book Value: $14.39 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 3,181,920,000
• Free Float: 3,180,650,000
• Market Cap: $46.15 billion
• Optionable: Optionable
• Beta: 0.23